183 related articles for article (PubMed ID: 31388185)
21. Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells.
Song M; Nishihara R; Cao Y; Chun E; Qian ZR; Mima K; Inamura K; Masugi Y; Nowak JA; Nosho K; Wu K; Wang M; Giovannucci E; Garrett WS; Fuchs CS; Ogino S; Chan AT
JAMA Oncol; 2016 Sep; 2(9):1197-206. PubMed ID: 27148825
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer.
Huang CY; Chiang SF; Ke TW; Chen TW; You YS; Chen WT; Chao KSC
Sci Rep; 2018 Oct; 8(1):15658. PubMed ID: 30353144
[TBL] [Abstract][Full Text] [Related]
23. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
[TBL] [Abstract][Full Text] [Related]
24. Intraepithelial tumour infiltrating lymphocytes are associated with absence of tumour budding and immature/myxoid desmoplastic reaction, and with better recurrence-free survival in stages I-III colorectal cancer.
González IA; Bauer PS; Liu J; Chatterjee D
Histopathology; 2021 Jan; 78(2):252-264. PubMed ID: 32654226
[TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation.
Digiacomo N; Bolzacchini E; Veronesi G; Cerutti R; Sahnane N; Pinotti G; Bregni M; Artale S; Verusio C; Crivelli F; Capella C; Sessa F; Furlan D
Clin Colorectal Cancer; 2019 Jun; 18(2):e251-e260. PubMed ID: 30638691
[TBL] [Abstract][Full Text] [Related]
26. Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score.
Dawson H; Christe L; Eichmann M; Reinhard S; Zlobec I; Blank A; Lugli A
Histopathology; 2020 Mar; 76(4):572-580. PubMed ID: 31560788
[TBL] [Abstract][Full Text] [Related]
27. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
[TBL] [Abstract][Full Text] [Related]
28. The inhibitory receptor CD94/NKG2A on CD8
Eugène J; Jouand N; Ducoin K; Dansette D; Oger R; Deleine C; Leveque E; Meurette G; Podevin J; Matysiak T; Bennouna J; Bezieau S; Volteau C; Thomas WEA; Chetritt J; Kerdraon O; Fourquier P; Thibaudeau E; Dumont F; Mosnier JF; Toquet C; Jarry A; Gervois N; Bossard C
Mod Pathol; 2020 Mar; 33(3):468-482. PubMed ID: 31409873
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
[TBL] [Abstract][Full Text] [Related]
30. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
Salama P; Phillips M; Grieu F; Morris M; Zeps N; Joseph D; Platell C; Iacopetta B
J Clin Oncol; 2009 Jan; 27(2):186-92. PubMed ID: 19064967
[TBL] [Abstract][Full Text] [Related]
31. The in situ local immune response, tumour senescence and proliferation in colorectal cancer.
Roxburgh CS; Richards CH; Macdonald AI; Powell AG; McGlynn LM; McMillan DC; Horgan PG; Edwards J; Shiels PG
Br J Cancer; 2013 Oct; 109(8):2207-16. PubMed ID: 24022192
[TBL] [Abstract][Full Text] [Related]
32. Differential gene expression of tumor-infiltrating CD8
Saleh R; Sasidharan Nair V; Toor SM; Taha RZ; Murshed K; Al-Dhaheri M; Khawar M; Petkar MA; Abu Nada M; Al-Ejeh F; Elkord E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948653
[TBL] [Abstract][Full Text] [Related]
33. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
34. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability.
Prall F; Dührkop T; Weirich V; Ostwald C; Lenz P; Nizze H; Barten M
Hum Pathol; 2004 Jul; 35(7):808-16. PubMed ID: 15257543
[TBL] [Abstract][Full Text] [Related]
36. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
37. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
38. Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer.
Chaput N; Svrcek M; Aupérin A; Locher C; Drusch F; Malka D; Taïeb J; Goéré D; Ducreux M; Boige V
Br J Cancer; 2013 Aug; 109(4):1013-22. PubMed ID: 23868006
[TBL] [Abstract][Full Text] [Related]
39. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.
Diederichsen AC; Hjelmborg Jv; Christensen PB; Zeuthen J; Fenger C
Cancer Immunol Immunother; 2003 Jul; 52(7):423-8. PubMed ID: 12695859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
